Vor Biopharma Inc.

Item 5. Other Information

Director and Officer Trading Arrangements

During the quarter ended June 30, 2025, no director or officer, as defined in Rule 16a-1(f), adopted orterminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," each as defined in Regulation S-K Item 408, except as follows:

•

On April 24, 2025, Eyal C. Attar, M.D., the Company’s former Chief Medical Officer, terminated a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act for the sale of 9,478 sharesof common stock between June 3, 2024 and June 30, 2025 (the “Sales Period”) plus up to 36,562 additional shares of common stock that may be acquired by Dr. Attar in connection with the settlement of restricted stock units during the

Sales Period, net of shares withheld to satisfy tax withholding obligations, so long as the market price of the Company’s common stock is higher than certain minimum thresholds specified in the trading plan.

Lease Agreement

On August 12, 2025, we entered into a lease agreement (the “Lease Agreement”) with 500 Boylston & 222 Berkeley Owner (DE) LLC with respect to 8,391 square feet of office space located at 500 Boylston Street, Boston, MA 02116 (the “Premises”) for our principal executive offices. The commencement date of the lease is the earlier of when we enter into possession of the Premises or September 1, 2025 (the “Term Commencement Date”), and the lease will expire 72 full calendar months after the Term Commencement Date (the “Initial Term”), unless terminated earlier in accordance with the Lease Agreement.

The annual base rent under the Lease Agreement initially will be $440,000 for the first year of the Initial Term, $530,400 for the second year, $698,400 for the third year, and then will increase by 2% per year for each year of the Initial Term thereafter. We will also be responsible for the payment of additional rent to cover our proportionate share of the annual operating and tax expenses for the Premises. In connection with entering into the Lease Agreement, we executed and delivered a letter of credit in the amount of $167,820 to secure our obligations under the Lease Agreement.

We have the option to extend the term for one additional five-year period, which is exercisable by written notice delivered not less than 12 months and not more than 15 months prior to the expiration of the Initial Term and subject to customary conditions, including that no default under the Lease Agreement exists.

The foregoing description of the Lease Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Lease Agreement, a copy of which is filed as Exhibit 10.10 to this Quarterly Report on 10-Q.